|MDACC Study No:||2013-0907 (clinicaltrials.gov NCT No: NCT02029443)|
|Title:||A Phase 1, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia|
|Principal Investigator:||Susan O'Brien|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of ACP-196 that can be given to patients with CLL. The safety of ACP-196 will
also be studied, and whether it can help to control the disease. This is the
first study using ACP-196 in humans.